Technical Use of Angiotensin I/II (1-5) in Renin-Angiotensin System Research

What This Product Solves

Angiotensin I/II (1-5) (SKU A1047) is a short, biologically active peptide fragment—Asp-Arg-Val-Tyr-Ile—derived from the initial five amino acids of angiotensin I and II. This product enables precise modeling of the renin-angiotensin system (RAS), a critical pathway for blood pressure regulation and aldosterone release stimulation. By supplying researchers with a chemically defined peptide, it supports controlled investigations of vasoconstrictor activity and sodium retention mechanisms relevant to hypertension and renal function. The narrow mechanistic action and defined sequence make it suitable for focused cardiovascular and renal research, while its solubility and storage requirements set clear experimental boundaries for reproducibility (source: product_spec).

For a further technical overview on RAS workflows using this peptide, see "Technical Guide: Angiotensin I/II (1-5) in RAS Research", which details its specific applications in blood pressure and aldosterone studies. Additionally, "Technical Use of Angiotensin I/II (1-5) in RAS Research" discusses its suitability for cardiovascular and renal modeling workflows.

Protocol Parameters

• assay: Peptide stock preparation | value_with_unit: Dissolve at ≥66.5 mg/mL in DMSO or ≥69.5 mg/mL in ethanol | applicability: Preparation of concentrated stock solutions for in vitro or ex vivo RAS modeling assays | rationale: The peptide is insoluble in water but achieves high solubility in DMSO and ethanol as specified | source_type: product_spec
• assay: Storage stability | value_with_unit: Store at -20°C (solid) | applicability: Long-term preservation of peptide integrity for repeated experimental use | rationale: Low temperature storage minimizes hydrolysis and oxidation of the peptide backbone | source_type: product_spec
• assay: Working concentration (recommendation) | value_with_unit: Prepare working dilutions in DMSO or ethanol immediately before use; avoid aqueous pre-dilution | applicability: Prevents precipitation or loss of bioactivity in physiological assays | rationale: The peptide's insolubility in water can lead to aggregation or inconsistent delivery if not freshly diluted | source_type: workflow_recommendation

Workflow Setup and QC Checklist

• Source the peptide as a lyophilized solid and immediately store at -20°C upon receipt to maintain stability (source: product_spec).
• For in vitro or ex vivo studies, first weigh the required amount under low-humidity conditions to avoid moisture uptake.
• Dissolve the peptide at the recommended solubility in DMSO (≥66.5 mg/mL) or ethanol (≥69.5 mg/mL), vortexing gently to ensure complete dissolution.
• Prepare aliquots of stock solution to minimize freeze-thaw cycles, which can degrade peptide quality.
• For assay use, dilute the stock in the final assay buffer or medium immediately before application, ensuring the vehicle (DMSO or ethanol) concentration is compatible with cellular or tissue models.
• Monitor for precipitation or incomplete dissolution visually or by turbidity check prior to dosing.
• Maintain batch records for each preparation, including lot number, preparation date, and solvent used, to support reproducibility.

Common Failure Modes and Fixes

• Incomplete dissolution: If visible particulates remain after vortexing in DMSO or ethanol, ensure solvent temperature is room temperature and extend agitation; avoid water as a primary solvent due to insolubility (source: product_spec).
• Peptide degradation: Repeated freeze-thaw cycles or prolonged exposure to ambient humidity may result in loss of activity; use single-use aliquots and minimize time at room temperature.
• Precipitation in assay buffer: If precipitation occurs upon dilution into aqueous media, verify that the vehicle concentration is below cellular toxicity thresholds but sufficient to maintain peptide in solution. Prepare fresh working solutions for each experiment.
• Batch-to-batch variability: Maintain strict records of preparation conditions. If variability is observed, compare with historic QC data and verify solvent quality and storage conditions.

Scope and Limitations

• Angiotensin I/II (1-5) is intended for modeling defined steps in the renin-angiotensin system, including vasoconstriction and aldosterone release in cardiovascular and renal research contexts.
• Its activity and solubility profile do not support studies in unrelated peptide signaling pathways, general peptide hormone research, or non-cardiovascular/renal mechanistic investigations (source: internal_article).
• Applications requiring aqueous stock solutions or high-throughput screening in water-based systems are not feasible due to insolubility.
• Mechanistic exploration outside blood pressure regulation and sodium retention/aldosterone signaling is not advised, as supported by product and internal workflow guidance.

Conclusion

Angiotensin I/II (1-5) (Asp-Arg-Val-Tyr-Ile peptide) is a practical tool for precise, controlled studies of blood pressure regulation and aldosterone signaling within the renin-angiotensin system. Its use is best confined to cardiovascular and renal modeling workflows, where strict adherence to solubility, storage, and preparation protocols ensures experimental integrity. For further details or to source this compound, refer to Angiotensin I/II (1-5) at APExBIO.